海辰药业(300584) - 2022 Q4 - 年度财报

Financial Performance - In 2022, the company achieved operating revenue of 526 million RMB, a year-on-year decrease of 8.97%[5] - The net profit attributable to shareholders was 32.45 million RMB, down 88.65% year-on-year, while the net profit excluding non-recurring gains and losses increased by 30.79% to 31.46 million RMB[5] - The significant decline in net profit was primarily due to a fair value change gain of 306.13 million RMB recognized in 2021, which contributed to a net profit of 260.21 million RMB that year[5] - The cash flow from operating activities was negative at -¥5,819,338.75, a decline of 109.71% from ¥59,940,771.89 in 2021[23] - The basic earnings per share dropped to ¥0.2704, down 88.65% from ¥2.3823 in 2021[23] - Total assets at the end of 2022 were ¥1,293,945,410.29, a slight decrease of 0.62% from ¥1,302,008,303.05 in 2021[23] - The company reported a total distributable profit of RMB 607,536,449.71 for the year, but did not propose any cash dividend distribution for 2022[154] Dividend and Shareholder Engagement - The company plans to distribute no cash dividends and no bonus shares for the year, with a capital reserve transfer of 0 shares for every 10 shares held[6] - The annual shareholders meeting had a participation rate of 62.17% on May 16, 2022[117] - The first extraordinary shareholders meeting had a participation rate of 62.04% on June 27, 2022[117] - The second extraordinary shareholders meeting also had a participation rate of 62.04% on July 15, 2022[118] - The company is committed to maintaining a high level of shareholder engagement as evidenced by the participation rates in meetings[117][118] Market and Product Development - The company aims to improve operational performance in 2023, despite the challenges faced in the previous year[5] - The company’s future outlook includes potential market expansion and new product development strategies[5] - The company is actively developing new products, with plans to submit consistency evaluation applications for several drugs in 2023, including Sodium Thiosulfate and Acetylcysteine injection[54] - The company has established a complete procurement, production, and sales system, ensuring stable supply and quality control in compliance with GMP standards[43][45] - The company is expanding its marketing network by developing partnerships with chain pharmacies and online channels, creating a multi-channel marketing strategy[49] Research and Development - The company has a strong R&D capability with over 60 dedicated personnel and has undertaken more than 20 national and provincial-level technology projects, enhancing its innovation in high-end generic and innovative drug development[46][47] - Research and development (R&D) investment amounted to ¥34,884,000.84 in 2022, representing 6.63% of operating revenue, a decrease from 10.01% in 2021[82] - The company has made significant progress in R&D projects, with multiple products nearing production approval, indicating a strong pipeline for future growth[80] - The company is focused on establishing quality standards for new raw materials and formulations, which is expected to enrich its product offerings[81] Regulatory Compliance and Risk Management - The management highlighted risks including changes in industry policies, new drug development risks, and a decline in market share for the main product Torasemide[5] - The company is committed to maintaining compliance with GMP standards and regulatory requirements from NMPA and FDA[17] - The company is aware of potential investment risks related to its new projects and will monitor market conditions closely[106] - The company emphasizes the importance of effective management and coordination as it expands its operations and increases the number of subsidiaries[106] Environmental Responsibility - The company has established comprehensive environmental management systems and complies with national and local environmental regulations[167] - The wastewater discharge meets the standards set by GB/T31962-2015 and DB32/939-2020, ensuring compliance with environmental laws[168] - The company has implemented measures to control emissions of volatile organic compounds (VOCs), with a total discharge of 3.42 tons, which is within the regulatory limits[169] - The company invested 1.7888 million yuan in environmental governance and protection during the reporting period[177] Governance and Management - The company has established a comprehensive governance structure, including a board of directors and supervisory board, to ensure effective decision-making and oversight[111] - The company has a performance evaluation and incentive mechanism for directors and senior management linked to company performance[113] - The company has implemented a profit distribution plan that considers both short-term and long-term shareholder interests[179] - The company has a structured governance framework, including a board of directors and an audit committee, to ensure compliance with laws and regulations[159] Employee Engagement and Welfare - Employee welfare initiatives included organizing multiple health check-ups and enhancing facilities such as a mother-baby room and fitness center[180] - The company organized 213 training sessions with a total of 1,084 training hours during the reporting period, aiming to enhance employee skills and company cohesion[149] - The total number of employees at the end of the reporting period is 549, with 437 in the parent company and 112 in major subsidiaries[147] - The company has a robust governance structure that includes a shareholders' meeting, board of directors, and supervisory board to protect minority shareholders' rights[179]